Cargando…

Prognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer

BACKGROUND: A family history can be a valuable tool in the era of precision medicine. Although a few studies have described an association of family history of lung cancer with EGFR activating mutation, their impact on survival of lung cancer patients is unclear. METHODS: The study included consecut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jung Soo, Cho, Min Seong, Nam, Jong Hyeon, Kim, Hyun-Jung, Choi, Kyeng-Won, Ryu, Jeong-Seon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423629/ https://www.ncbi.nlm.nih.gov/pubmed/28486527 http://dx.doi.org/10.1371/journal.pone.0177015

Ejemplares similares

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation
por: Kim, Jung Soo, et al.
Publicado: (2017)

Small-cell Lung Cancer Presenting as Fatal Pulmonary Hemorrhage
por: Lim, Jun Hyeok, et al.
Publicado: (2018)

Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
por: Lee, Yong Seok, et al.
Publicado: (2017)

Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching
por: Lim, Jun Hyeok, et al.
Publicado: (2018)

Gender Differences in Susceptibility to Smoking among Patients with Lung Cancer
por: Ryu, Jeong-Seon, et al.
Publicado: (2011)

Multiple Hypercoagulability Disorders at Presentation of Non-Small-Cell Lung Cancer
por: Lee, Jeong Min, et al.
Publicado: (2014)

EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
por: Jo, Ukhyun, et al.
Publicado: (2014)

Indoor Radon and Lung Cancer: National Radon Action Plans Are Urgently Required
por: Nam, Hae-Seong, et al.
Publicado: (2018)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer
por: Lee, Sangah, et al.
Publicado: (2021)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

Heterogeneous radiological response to chemotherapy is associated with poor prognosis in advanced non‐small‐cell lung cancer
por: Ryu, Woo Kyung, et al.
Publicado: (2021)

Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Occupational Lung Cancer Surveillance in South Korea, 2006-2009
por: Leem, Jong-Han, et al.
Publicado: (2010)

Role of prognostic nutritional index in postoperative radiotherapy for non‐small cell lung cancer
por: Ryu, Hyejo, et al.
Publicado: (2023)

Differentiation of primary lung cancer from solitary lung metastasis in patients with colorectal cancer: a retrospective cohort study
por: Lee, Jong Eun, et al.
Publicado: (2021)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Survival prediction of tuberous sclerosis complex gene variant in patients with advanced non-small-cell lung cancer treated with platinum doublet
por: Ryu, Jeong-Seon, et al.
Publicado: (2019)

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
por: Kim, Insu, et al.
Publicado: (2019)

Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry
por: Kim, Ho Cheol, et al.
Publicado: (2019)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Erratum: Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
por: Yoon, Hee-Young, et al.
Publicado: (2020)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

A national survey of lung cancer specialists’ views on low-dose CT screening for lung cancer in Korea
por: Shin, Dong Wook, et al.
Publicado: (2018)

Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression
por: SONG, DAE HYUN, et al.
Publicado: (2016)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
por: Ha, Sang Yun, et al.
Publicado: (2015)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

Clinical implication of interstitial lung abnormality in elderly patients with early‐stage non‐small cell lung cancer
por: Cho, Seong Woo, et al.
Publicado: (2022)

Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015
por: Jeon, Da Som, et al.
Publicado: (2023)

Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis
por: Kim, Kwangho, et al.
Publicado: (2023)

Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer
por: Na, Im II, et al.
Publicado: (2007)

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
por: Kang, Noeul, et al.
Publicado: (2022)

Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
por: Kim, Jeong-Oh, et al.
Publicado: (2020)

Association of Family History With Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients With Colorectal Cancer
por: Park, Yehyun, et al.
Publicado: (2019)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer
por: Kim, Seon-Kyu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g2av8a4mfgdjagulbl4b03j03b